41.22
0.05 (0.12%)
| Previous Close | 41.17 |
| Open | 40.71 |
| Volume | 1,480,275 |
| Avg. Volume (3M) | 2,085,654 |
| Market Cap | 3,535,624,704 |
| Price / Earnings (Forward) | 23.36 |
| Price / Sales | 94.27 |
| Price / Book | 1.75 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -180.96% |
| Diluted EPS (TTM) | -4.34 |
| Quarterly Revenue Growth (YOY) | -82.30% |
| Total Debt/Equity (MRQ) | 11.58% |
| Current Ratio (MRQ) | 22.07 |
| Operating Cash Flow (TTM) | -142.77 M |
| Levered Free Cash Flow (TTM) | -29.27 M |
| Return on Assets (TTM) | -13.04% |
| Return on Equity (TTM) | -19.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CRISPR Therapeutics AG | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 1.65% |
| % Held by Institutions | 84.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 120.00 (Truist Securities, 191.12%) | Buy |
| Median | 73.00 (77.10%) | |
| Low | 32.00 (Morgan Stanley, -22.37%) | Sell |
| Average | 71.42 (73.27%) | |
| Total | 7 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 37.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 07 May 2025 | 82.00 (98.93%) | Buy | 0.000 |
| 13 Feb 2025 | 84.00 (103.78%) | Buy | 43.49 | |
| Needham | 07 May 2025 | 81.00 (96.51%) | Buy | 0.000 |
| 09 Apr 2025 | 84.00 (103.78%) | Buy | 34.89 | |
| Citigroup | 18 Feb 2025 | 82.00 (98.93%) | Buy | 52.22 |
| Evercore ISI Group | 14 Feb 2025 | 99.00 (140.17%) | Buy | 49.72 |
| Morgan Stanley | 14 Feb 2025 | 32.00 (-22.37%) | Sell | 49.72 |
| Goldman Sachs | 13 Feb 2025 | 57.00 (38.28%) | Hold | 43.49 |
| HC Wainwright & Co. | 13 Feb 2025 | 65.00 (57.69%) | Buy | 43.49 |
| JMP Securities | 13 Feb 2025 | 86.00 (108.64%) | Buy | 43.49 |
| Stifel | 13 Feb 2025 | 49.00 (18.87%) | Hold | 43.49 |
| Barclays | 12 Feb 2025 | 56.00 (35.86%) | Hold | 43.30 |
| RBC Capital | 12 Feb 2025 | 48.00 (16.45%) | Hold | 43.30 |
| Truist Securities | 12 Feb 2025 | 120.00 (191.12%) | Buy | 43.30 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 May 2025 | Announcement | CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 |
| 03 Apr 2025 | Announcement | CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference |
| 02 Apr 2025 | Announcement | Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine |
| 26 Mar 2025 | Announcement | CRISPR Therapeutics Announces Transition of Chief Operating Officer |
| 04 Mar 2025 | Announcement | The Future of Stem Cell Investing: Spotlight on Smaller Innovators |
| 26 Feb 2025 | Announcement | CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference |
| 11 Feb 2025 | Announcement | CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |